Annual report pursuant to Section 13 and 15(d)

Aytu Divestiture - Summary of Cash Flows (Details)

v3.20.1
Aytu Divestiture - Summary of Cash Flows (Details) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Operating activities      
Gain on Aytu Divestiture   $ (7,964,924) $ 0
Pediatric Portfolio      
Operating activities      
Gain on Aytu Divestiture $ (8,000,000)    
Pediatric Portfolio | Discontinued Operations, Disposed of by Sale      
Operating activities      
Amortization   2,425,083 2,703,896
Impairment of intangible assets   1,449,121 0
Stock-based compensation, excluding amount included within gain on sale of Pediatric Portfolio   327,180 137,082
Amortization of inventory fair value adjustment associated with acquisition of TRx and Avadel Pediatric Product   107,271 170,629
Non-cash interest expense   0 302,882
Gain on Aytu Divestiture $ (8,000,000) (7,964,924) 0
Change in fair value of contingent consideration   $ 247,042 $ 169,289